Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NAVB Stock Summary
- NAVB has a higher market value than merely 1.92% of US stocks; more precisely, its current market capitalization is $7,682,925.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -7.11 for NAVIDEA BIOPHARMACEUTICALS INC; that's greater than it is for just 2.32% of US stocks.
- Revenue growth over the past 12 months for NAVIDEA BIOPHARMACEUTICALS INC comes in at -76.59%, a number that bests only 1.92% of the US stocks we're tracking.
- Stocks that are quantitatively similar to NAVB, based on their financial statements, market capitalization, and price volatility, are VTVT, ACER, GEOS, ICPT, and ESPR.
- NAVB's SEC filings can be seen here. And to visit NAVIDEA BIOPHARMACEUTICALS INC's official web site, go to www.navidea.com.
NAVB Valuation Summary
- In comparison to the median Healthcare stock, NAVB's price/earnings ratio is 103.06% lower, now standing at -0.6.
- Over the past 243 months, NAVB's EV/EBIT ratio has gone up 1.6.
Below are key valuation metrics over time for NAVB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NAVB | 2022-09-23 | 35.8 | -1.7 | -0.6 | -0.7 |
| NAVB | 2022-09-22 | 35.8 | -1.7 | -0.6 | -0.7 |
| NAVB | 2022-09-21 | 37.3 | -1.8 | -0.6 | -0.7 |
| NAVB | 2022-09-20 | 38.7 | -1.9 | -0.7 | -0.7 |
| NAVB | 2022-09-19 | 38.7 | -1.9 | -0.7 | -0.7 |
| NAVB | 2022-09-16 | 41.2 | -2.0 | -0.7 | -0.7 |
NAVB Growth Metrics
- Its 3 year cash and equivalents growth rate is now at -17.23%.
- The 2 year net income to common stockholders growth rate now stands at -4.99%.
- Its 4 year revenue growth rate is now at -96.63%.
The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 0.204256 | -9.436224 | -12.0767 |
| 2022-03-31 | 0.407776 | -9.711727 | -11.75128 |
| 2021-12-31 | 0.531513 | -10.21815 | -11.73093 |
| 2021-09-30 | 0.700416 | -10.04659 | -11.08244 |
| 2021-06-30 | 0.872423 | -10.66532 | -11.9495 |
| 2021-03-31 | 0.882478 | -10.285 | -11.67886 |
NAVB Stock Price Chart Interactive Chart >
NAVB Price/Volume Stats
| Current price | $0.26 | 52-week high | $1.81 |
| Prev. close | $0.27 | 52-week low | $0.23 |
| Day low | $0.26 | Volume | 26,647 |
| Day high | $0.28 | Avg. volume | 194,921 |
| 50-day MA | $0.39 | Dividend yield | N/A |
| 200-day MA | $0.76 | Market Cap | 8.02M |
Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.
Latest NAVB News From Around the Web
Below are the latest news stories about NAVIDEA BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NAVB as an investment opportunity.
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of StockholdersDUBLIN, Ohio, September 30, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua ("Josh") Wilson to its Board of Directors, effective September 30, 2022, with a term ending concurrently with the Company’s 2024 annual stockholders’ meeting. |
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual MeetingDUBLIN, Ohio, September 15, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the Company’s completed NAV3-31 Phase 2B clinical study as well as the preliminary results of its ongoing NAV3-32 Phase 2B study have been accepted for presentation as posters at the Annual Meeting of the American College of Rheumatology ("ACR") |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares! |
Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Call TranscriptNavidea Biopharmaceuticals, Inc. (NAVB) Q2 2022 Earnings Conference Call September 08, 2022, 04:00 PM ET Company Participants Michael Rosol – CMO Alex Cappello - Vice Chair Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Fred Zaino - Keystone Michael Okunewitch - Maxim Group Presentation Operator Greetings. Welcome to the Navidea Quarter Two 2022 Earnings Call and Business Update. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] And please note that this conference is being recorded.... |
Edited Transcript of NAVB.A earnings conference call or presentation 8-Sep-22 8:00pm GMTQ2 2022 Navidea Biopharmaceuticals Inc Earnings Call and Business Update |
NAVB Price Returns
| 1-mo | -18.75% |
| 3-mo | -61.76% |
| 6-mo | -66.67% |
| 1-year | -85.31% |
| 3-year | -61.82% |
| 5-year | -96.98% |
| YTD | -74.00% |
| 2021 | -53.49% |
| 2020 | 70.63% |
| 2019 | -37.00% |
| 2018 | -72.22% |
| 2017 | -43.75% |
Continue Researching NAVB
Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...